Compare Regeneron Pharmaceuticals Inc (REGN) vs SiTime Corporation (SITM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs SiTime Corporation — how do they compare? Regeneron Pharmaceuticals Inc trades at $652 (market cap $70.79B), while SiTime Corporation trades at $589.85 (market cap $17.66B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 4× SiTime Corporation's market cap, and Regeneron Pharmaceuticals Inc pays a 0.56% dividend while SiTime Corporation pays none. Which is the better fit depends on your goals.
| REGN | SITM | |
|---|---|---|
Market Cap | $70.79B | $17.66B |
Sector | Health | Technology |
52-Week High | $812.27 | $901.60 |
52-Week Low | $545.46 | $190.16 |
Enterprise Value | $64.74B | $16.88B |
Dividend Yield | 0.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
SITM trades at $555.15, showing minimal daily movement with a 0.03% gain. The stock faces technical headwinds with a bearish moving average signal, though RSI levels suggest potential oversold conditions. Fundamentally, the company demonstrates strong revenue growth and consistent earnings beats, but operates at a net loss with negative margins. Recent developments include the completed acquisition of Renesas' timing business and strong AI-driven demand, with Q2 2026 results due August 5, 2026.
Analyst consensus remains strongly bullish with a $825 price target representing 49% upside potential. Key opportunities include accelerating AI infrastructure demand and strategic acquisitions, while risks center on continued profitability challenges and high valuation multiples. The company's growth trajectory appears promising, but investors should monitor the transition to sustainable profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About SiTime Corporation
SiTime Corporation is a leading provider of MEMS-based silicon timing solutions used in various electronic applications. The company’s products, including oscillators, resonators, and clock ICs, are designed to replace traditional quartz-based timing devices, offering superior performance, reliability, and smaller size in harsh environments. SiTime's solutions are adopted across high-growth markets such as 5G, data centers, industrial IoT, and automotive, positioning the company as a key enabler for next-generation electronic systems.
Read more on SITM →
